WORCESTER BUSINESS JOURNAL – CeQur has broken ground on an expansion of its Marlborough facility that will double its size and allow it to increase the workforce by 100 over the next two years.
The maker of simple insulin infusion for people with diabetes is undertaking the expansion in preparation for the launch of the company’s three-day insulin infusion device, PAQ. When work is completed later this year, it will bring the facility’s size to 25,000 square feet, according to a release from CeQur. The expansion includes a new clean room, labs and a manufacturing line. The new space will also allow the company to grow its Marlborough employee base from 50 to 150, according to an announcement.
“The continued investment and expansion of companies like CeQur speaks to Massachusetts’ leadership in life sciences and the medical device industry,” Massachusetts Governor Charlie Baker said in a statement. “The expansion of their facility in Marlborough and creation of new job opportunities is important not only to the people of the Commonwealth, but all those who can benefit from continued advancements in treatments for diabetes around the world.”
Clinical studies have demonstrated that people using PAQ to replace their multiple daily insulin injections experience significant improvement in glycemic control and high device satisfaction, according to the company.
CeQur is headquartered in Horw, Switzerland, with operations in Nordborg, Denmark and Marlborough.
This article by Sam Bonacci originally appeared here.